European Union:
CHMP Recommends Extensions For Seven Therapeutic Indications
12 November 2015
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
During its October 19–22, 2015 meetings, the Committee for
Medicinal Products for Human Use ("CHMP") recommended
extensions of indication for Cubicin, Edurant,
Emend, Volibris, Xalkori, and two extensions of indication for
Cosentyx.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from European Union
Manatt Health: Health AI Policy Tracker
Manatt, Phelps & Phillips LLP
The purpose of this quarterly tracker is to identify key federal and state health AI policy activity. Below reflects federal legislative and regulatory activity to date related to AI...